Estudio Farmacoeconómico costo-efectividad del uso de Ceftriaxona y Cefazolina en pacientes de cirugía traumatológica postoperatorio y urología del Hospital Andino Alternativo de Chimborazo.

Abstract

This work aims to study the cost-effectiveness of the use of cefazolin and ceftriaxone like antibiotics, which are used in post-operative traumatological surgery and urology area at Chimborazo Andean Alternative Hospital. To carried out this study were selected 138 patients who were administered ceftriaxone and cefazolin in their treatment, the clinical examinations were checked in order to get information like: age, sex, origin, type of surgery, adverse reactions, drug used, dosage, days of hospitalization, complications, relapses and consultations; this allowed to calculate individualized patient costs for this was taken into account medical fee, the dose and the inputs used, costs per minute of time spent by the nurse who prepare and administer the medicine. SPSS 18 software was used for statistical calculations; it was found that the drug has an average cefazolin for medical care, hospitalization days, medicines and medical supplies of $ 1021.22 ± $ 519.02, while ceftriaxone has an average cost of $ 1495.43 ± $ 812.25, being statistically cefazolin the drug with lower cost. Chi square test was used to evaluate the effectiveness, getting that any of the two treatments give significant differences. To study the cost-effectiveness of ceftriaxone and cefazolin use applied a cost-effectiveness analysis (CEA), measured in patients who tested a positive treatment where ceftriaxone ($ 0.051) has lower cost than cefazolin ($ 0.095), concluding that there are significant differences in the cost of medical care, hospitalization days, medical supplies and medicines with ceftriaxone and cefazolin, being the effectiveness of the two drugs like. It recommend further studies on adverse reactions and antibiotic resistance in older adults, both ceftriaxone and cefazolin, considering that these are multipathology and polypharmacy patients.